The distribution of continuous glucose monitoring system market share is highly concentrated among a few "Big Three" players: Abbott, Dexcom, and Medtronic. These giants have created powerful moats through extensive patent portfolios and deep integration with insulin pump manufacturers. For example, Dexcom’s G-series sensors are the primary choice for "automated insulin delivery" systems, giving them a significant advantage in the Type 1 market. Abbott, with its FreeStyle Libre line, has dominated the "flash" and lower-cost segments, appealing to a massive audience of Type 2 users through its easy "scan-and-go" interface.

Despite the dominance of these titans, the landscape is seeing a new wave of competition from tech companies and regional players. Startups are focusing on "disruptive" form factors, such as wearable rings or ear-mounted sensors, that aim to eliminate the "medical" look of traditional patches. In regions like India, local brands are launching Bluetooth-enabled CGMs at a fraction of the cost of Western imports, tailored specifically for the local socio-economic environment. This fragmentation at the "entry-level" of the market is forcing the established leaders to accelerate their innovation cycles to maintain their premium positioning.